Everyone loses when the opinions of qualified women are not heard. The BMJ Gender Diversity Group shares how you can help us improve the gender balance of expert voices in […]
Elizabeth Loder
Elizabeth Loder: Rich journals, poor journals, and why we should mind the gap
Elite medical journals are resource-rich but lower-tier journals struggle […]
Elizabeth Loder: Gun violence in the US—the kids (and Miss America) will fix it for us
Will the Parkland students and the #NeverAgain movement be able to keep up the momentum? […]
Elizabeth Loder: The journal that never sleeps
Elizabeth Loder explains why decision letters from The BMJ often arrive quickly and at odd hours […]
Elizabeth Loder: The persistent problem of unregistered clinical trials
How can we get to zero unregistered clinical trials? Elizabeth Loder discusses. […]
Elizabeth Loder: Should orange be the new black for price-gouging pharma execs?
One thing’s for sure: Heather Bresch, the CEO of Mylan Pharmaceuticals, looks good in orange. She’s the subject of a recent New York Times article that opens by declaring “America has […]
Elizabeth Loder: US medical specialty boards: accountable to whom, for what, and how?
Elizabeth Loder examines charges of lax oversight and governance at organizations that assess doctors. The medical specialty boards that test and certify US doctors are facing a tough test of […]
Elizabeth Loder: Has the American Board of Internal Medicine lost its way?
Elizabeth Loder examines the emergence of organized US physician opposition to revalidation requirements. Something remarkable is happening right now in American medicine. A unified physician movement has emerged that cuts […]
Elizabeth Loder on the proliferation of medical research reporting guidelines: A checklist too far?
If reporting guidelines and checklists are the answer, what is the problem? That’s easy: their development was motivated by the realization that critical information was vague, missing, or misreported in […]